Plasma Fractionation Market: Global Size, Share, Trends, Growth and Forecast 2022-2032

Plasma Fractionation Market: Overview and Definition

The Global Plasma Fractionation Market is expected to grow from USD 31.05 billion in 2021 to USD 52.58 billion by 2032, at a CAGR of 7.8% during the forecast period 2022-2032. Plasma fractionation is the process of separating blood plasma into its various components for therapeutic use. Plasma is the yellowish fluid component of blood that contains proteins, hormones, and other substances necessary for blood clotting and other functions.

The plasma fractionation market refers to the market for products and services related to the fractionation of blood plasma into its various components, such as albumin, immunoglobulin, and clotting factors. These products are used for a variety of medical applications, including the treatment of bleeding disorders, immune deficiencies, and other conditions.

The plasma fractionation market is a growing market, driven by the increasing demand for plasma-derived therapies and the growing aging population, which is more likely to require these treatments. The market is characterized by a large number of players, including both established companies and new entrants, and is dominated by a few key players, such as CSL Behring, Grifols, and Takeda.

Plasma, which contains a considerable concentration of different proteins, is the most crucial liquid component of the whole blood. Human plasma is a source of many other proteins, but only a few of these proteins are beneficial for producing therapeutic plasma products. It consists mainly of water containing only a small amount of minerals, salts, ions, nutrients, and proteins in the solution. A fraction of a plasma that is a blood component that is collected by the blood fractionation is classified as the various components of the blood plasma. After the fractionation of plasma, a wide range of life-saving products is obtained to prevent, manage, and treat various life-threatening human injuries and diseases, such as coagulation, immunoglobulin, and protease inhibitors, anticoagulants, albumins, and others.

Plasma Fractionation Market: Growth Drivers

Growing Adoption of Immunoglobulin to Bolster Market Growth

One of the predominant and crucial factors for market growth is the increased use of immunoglobulin to manage, treat and diagnose metabolic diseases worldwide. The high use of immunoglobulin will, therefore, magnify its dominance and improve market prospects. Immunoglobulin is a plasma-derived glycoprotein molecule that acts as an antibody. Constant research and development have been carried out to understand the effectiveness and therapeutic nature of immunoglobulin in treating complex diseases such as Alzheimer's and other autoimmune disorders. These factors are expected to drive the growth of the market cumulatively.

The market for Plasma Fractionation is driven by factors such as an increased amount of hemophilic patients, an increased prevalence of autoimmune diseases, an increasing prevalence of respiratory diseases and a growing generic population. The market is driven mainly by proteins derived from plasma that have several therapeutic applications. Some of the applications of plasma-derived proteins include biomarkers for diagnoses of disease, acute liver failure treatment, maintaining blood volume following traumas in surgery and immunological disorders.

In addition, one of the significant factors contributing to market growth is an increase in the number of hemophilic patients. Hemophilic patients require coagulation factors to be administered daily, which increases the global demand for plasma fractionation products.

In 2019, the global market for plasma fractionation was estimated to be over USD 25 billion. At a CAGR of 6.02 percent from 2020 to 2025, it is expected to grow.

One of the main factors hindering the market's growth is the high cost of plasma-derived protein, Hoverer, due to the costs associated with protein purification. In addition, strict government regulations, limited reimbursement, and the emergence of recombinant proteins as an alternative to proteins derived from plasma are expected to hinder the growth of the market for plasma fractionation to some degree.

Plasma Fractionation Market: Challenges

Stringent regulations: The plasma fractionation market is subject to stringent regulations, such as those related to the safety and efficacy of plasma-derived products. These regulations can be time-consuming and costly to comply with, which can limit the competitiveness of some companies in the market.

Shortage of plasma: There is a global shortage of plasma, which is a key raw material for plasma fractionation. This shortage is driven by a number of factors, including the increasing demand for plasma-derived therapies, a declining donor pool, and limited collection and processing capacity. This shortage can limit the growth of the plasma fractionation market, as companies struggle to secure the plasma they need to produce their products.

Competition from alternative therapies: The plasma fractionation market faces competition from alternative therapies, such as recombinant products, which are produced through genetic engineering rather than from plasma. These alternative therapies can offer advantages over plasma-derived products, such as lower risk of disease transmission and lower cost, which can limit the growth of the plasma fractionation market.

High cost of plasma-derived products: Plasma-derived products can be relatively expensive, which can limit their accessibility to some patients, especially in developing countries. This can create challenges for the plasma fractionation market, as companies struggle to make their products more affordable while maintaining profitability.

Intellectual property challenges: The plasma fractionation market is characterized by a high degree of intellectual property, including patents and trade secrets, which can limit competition and create barriers to entry for new entrants. This can make it difficult for companies to bring new products and technologies to market, which can limit the growth of the plasma fractionation market.

Plasma Fractionation Market: Segmentation

By Product

• immunoglobulin
• Intravenous immunoglobulin
• Subcutaneous Immunoglobulin
• Other immunoglobulin
• Coagulation Factor Concentrates
• Factor VIII
• Factor IX
• Von Willebrand Factor
• Prothrombin Complex Concentrate
• Fibrinogen Concentrates
• Factor XIII
• Albumin
• Protease Inhibitors
• Other Products

By Application

• Neurology
• Immunology
• Haematology
• Critical care
• Pulmonology
• Haemato-oncology
• Rheumatology
• Other Applications

By End User

• Hospitals & Clinics
• Clinical Research Laboratories
• Academic Institutes

By Geography:

- North America (U.S. & Canada)
- Europe (Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe)
- Asia Pacific (China, India, Japan, South Korea, Indonesia, Taiwan, Australia, New Zealand and Rest of Asia Pacific)
- Latin America (Brazil, Mexico and Rest of Latin America)
- Middle East & Africa (GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa and Rest of Middle East & Africa

Plasma Fractionation Market: Regional Synopsis

North America: North America is a significant market for plasma fractionation, with the United States being the largest market in the region. The United States is home to several leading plasma fractionation companies, as well as a large and aging population, which drives the demand for plasma-derived therapies.

Europe: Europe is also a significant market for plasma fractionation, with the market being driven by a growing aging population and the increasing demand for plasma-derived therapies. Europe is home to several leading plasma fractionation companies, as well as a supportive regulatory environment, which is driving growth in the market.

Asia-Pacific: Asia-Pacific is a rapidly growing market for plasma fractionation, driven by the increasing demand for plasma-derived therapies in countries such as China, India, and Australia. The increasing awareness of plasma-derived therapies and the growing aging population in Asia-Pacific are expected to drive growth in the market in the coming years.

In terms of region, the global market for plasma fractionation is divided into five regions: North America, Europe, Latin America, Asia Pacific, the Middle East, and Africa. In 2015, due to rising per capita healthcare spending in the U.S., Increasing demand for improved and advanced health facilities and increased adoption of new and advanced technologies were dominated by North America as a global plasma fractionation market. Due to increasing hemophilia prevalence among countries such as China and India and increasing aging in the Asia Pacific region,the highest CAGR is expected in the Asia Pacific region during the forecast period on the global plasma fractionation market.

Competitive Landscape

The report profiles various major market players such as

• CSL
• Baxter
• Kedrion S.p.A.
• Octapharma
• Grifols, S.A.
• Biotest AG
• Shire
• LFB
• Other Major & Niche Players

Competitive landscape analysis provides detailed strategic analysis of the company’s business and performance such as financial information, revenue breakup by segment and by geography, SWOT Analysis, key facts, company overview, business strategy, key product offerings, marketing and distribution strategies, new product development, recent news (acquisition, expansion, technology development, research & development and other market activities). The study also provides company’s positioning and market share of the overall market.

Timeline Considered for Analysis:

- 2021: Base Year
- 2022: Estimated Year
- 2022 to 2032: Forecast Period

Research Scope and Deliverables

Overview & Executive Summary
Market Drivers, Trends, Challenges and Opportunities
Market Size and Forecast Projections
Macroeconomic Indicators of Various Countries Impacting the Growth of the Market
Extensive Coverage of Industry Players including Recent Product Launches and Market Activities
Porter’s Five Force Analysis

Market Segmentation Analysis:
Industry report analyses the global plasma fractionation market by the following segments:
- Product
- Application
- End-User

Customization: We also offer customization’s in the industry report as per the company’s specific needs.

Key Questions Answered in the Plasma Fractionation Industry Report

• What is the overall market size in 2019? What will be the market growth during the forecast period i.e. 2020-2025?
• Which region would have high demand for product in the upcoming years?
• What are the factors driving the growth of the market?
• Which sub-market will make the most significant contribution to the market?
• What are the market opportunities for existing and entry-level players?
• What are various long-term and short-term strategies adopted by the market players?